Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?

Nature Clinical Practice Rheumatology volume 4, pages 398–399 (2008)Cite this article

boxed-textBreban M et al. (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58: 88–97

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. de Vries MK et al. (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66: 1252–1254

    Article  CAS  Google Scholar 

  2. Maini RN et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563

    Article  CAS  Google Scholar 

  3. Haibel H et al. (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66: 419–421

    Article  CAS  Google Scholar 

  4. Baert F et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608

    Article  CAS  Google Scholar 

  5. Pérez-Guijo VC et al. (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74: 254–258

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Author notes

  1. Rheumatology, Department of Medicine I, Charité Medical School, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany joachim.sieper@charite.de

Authors and Affiliations

  1. J Sieper is Professor and Head of Rheumatology in the Medical Department I at the University Hospital Charité (Campus Benjamin Franklin) in Berlin, Germany.,

    Joachim Sieper

Authors
  1. Joachim Sieper
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

J Sieper has declared that he is a consultant for, and has received speaker's bureau (honoraria) and grant/research support from, Abbott, Schering–Plough and Wyeth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sieper, J. Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?. Nat Rev Rheumatol 4, 398–399 (2008). https://doi.org/10.1038/ncprheum0846

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0846

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing